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been shown to be unhelpful in the diagnosis of fungal
disease. We therefore initiated the practice of nasal
endoscopy as part of our evaluation of HSCT patients who
had prolonged fever.
Methods: We performed a retrospective review of all
children who underwent HSCT at our institution from
January 2011 until June 2014. Children were identiﬁed who
underwent nasal endoscopy after a minimum of three days
of fever despite the initiation of broad-spectrum antibiotics
and who had negative bacterial blood cultures. The results of
the endoscopy and any cultures obtained were reviewed.
Demographic, clinical, microbiologic, management and
outcome data were collected.
Results: A total of 44 nasal endoscopieswereperformed in 42
children. Threeof the childrenhadpositivenasal endoscopies.
Two were asymptomatic and were found to have suspicious
lesions which were subsequently biopsied. Thesewere found
to be positive for Fusarium spp andRhizopus spp. The thirdhad
rapid development of eye swelling and sinus pain and was
found to have Rhizopus spp. The three children were then
treated with aggressive serial debridement and initiation of
multiagent antifungal therapy. All three of the children sur-
vived their fungal infection although one remains on anti-
fungal therapy.Mild discomfort during the procedurewas the
onlyadverse event related to the use of endoscopy reported in
this patient group. In those with a negative endoscopy, there
were no children who subsequently developed fungal sinus
disease. Three of these patients were later identiﬁed with a
fungal infection at other sites: one had bipolaris spp of the
skin, one had Aspergillus ﬂavus isolated from an endotracheal
tube aspirate and one had disseminated Histoplasmosis
capsulatum isolated on post-mortem examination.
Conclusions: We conclude that nasal endoscopy is safe and
effective in the evaluation of pediatric HSCT patients as part
of the evaluation of prolonged fever to rule out fungal
sinusitis. Early detection of fungal sinusitis by nasal
endoscopy and aggressive surgical and antifungal therapy
may improve the survival of HSCT patients.332
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Introduction: Letermovir (MK-8228) is a potent, once-daily
inhibitor of the cytomegalovirus (CMV) terminase complex
that is being developed for the prophylaxis of CMV
infection in transplant patients. This study evaluated the
pharmacokinetic interactions, safety and tolerability of
letermovir when coadministered in healthy subjects with
mycophenolate mofetil (MMF), which is the morpholi-
noethyl ester prodrug of mycophenolic acid (MPA).
Materials & Methods: This was an open label trial in 14
healthy female subjects that explored the pharmacokidsnetic
parameters of a single 1 mg oral dose of MMF administered
alone on day 1 and administered on day 12 with letermovir
given orally as 480 mg once daily from day 8 and continued
through day 16. Letermovir pharmacokinetics were assessedat single dose (day 5) and at steady state on day 12 (with
MMF) and on day 16 (alone following MMF washout).
Results: Coadministration of a single dose of 1 mg of MMF
with 480 mg daily letermovir at steady state had no effect on
the pharmacokinetics of MPA. The MPA AUC0-inf and Cmax
geometric mean ratios (GMRs) [90% conﬁdence interval] for
the comparison (MMF with letermovir/MMF alone) were
1.08 [0.96, 1.21] and 0.96 [0.81, 1.13], respectively. Coadmin-
istration of 480 mg daily letermovir at steady state with a
single dose of 1 mg MMF has no clinically meaningful effect
on the pharmacokinetics of letermovir with AUC0-24 and
Cmax GMR of 1.18 [1.04, 1.33] and 1.11 [0.92, 1.35], respec-
tively. The letermovir geometric mean accumulation ratio
(Day 16/Day 5) and 95% CI were 1.13 [0.90, 1.42] for AUC0-24
and 1.01 [0.79, 1.28] for Cmax, indicating that accumulation of
letermovir when administered as daily doses is minimal. All
related AEs were reported as mild in severity and resolved.
Following coadministration of letermovir and MMF, no
clinically meaningful changes were observed in clinical
laboratory values, vital signs, ECG or physical exam results.
Conclusions: Multiple dose administration of 480 mg leter-
movirdailywith a single doseof 1mgMMFwasgenerallywell
tolerated by the healthy subjects in this study. Co-adminis-
tration of letermovir with MMF had no clinically meaningful
effect on the PK of letermovir or MMF. Letermovir and MMF
may be coadministered without dose adjustment.333
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Introduction: While AH & ITP are recognized after CBT, the
incidence, severity, treatment response, & prognosis of these
complications is not established.
Methods: We evaluated AH/ITP in a day 100 landmark
analysis of 152 double-unit CBT recipients (median age 38
years, range 0.9-70) who were transplanted for hematologic
malignancies, engrafted & disease-free.
Results: Nine patients [median age 42 years (range 2-54),
median follow-up 50.6 months (range 7.6-105.4) have
developed autoimmune cytopenias (7 AH, 1 ITP, 1 both) for a
6% (95%CI: 3-11) 3-year cumulative incidence [median onset
8.6 months (range 5.8-24.5), Figure]. Six patients had severe
disease (Hb < 6 gm/dl &/or platelets < 20). Their lowest
counts (Hb 2.6-6.8 & platelets 0-4) were a median of 1 day
(range 0-94) after diagnosis. Six had grade II-IV acute
GVHD prior to AH/ITP, and all 9 patients developed AH/ITP
in the context of immunosuppression taper. There was no
association between AH/ITP and age, diagnosis, regimen
intensity, or recipient CMV serostatus. Treatment in the
ﬁrst week was IVIg/corticosteroids/rituximab in 3 patients,
whereas CSA dose was increased in 1, 2 had IVIg only, 2
